日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.

通过创新的基于 cVLP 的疫苗靶向 PCSK9,增强了 cVLP-HER2 疫苗在 HER2 阳性乳腺癌临床前模型中的治疗活性

Scalambra Laura, Ruzzi Francesca, Pittino Olga Maria, Semprini Maria Sofia, Cappello Chiara, Angelicola Stefania, Palladini Arianna, Nanni Patrizia, Goksøyr Louise, Fougeroux Cyrielle, Penichet Manuel L, Sander Adam Frederik, Lollini Pier-Luigi

A modular vaccine platform merging the rapid development of genetic vaccines with the immunogenicity of virus-like particles

一种模块化疫苗平台,融合了基因疫苗的快速开发和病毒样颗粒的免疫原性。

Sander, Adam F; Fougeroux, Cyrielle

Mosaic and cocktail capsid-virus-like particle vaccines for induction of antibodies against the EPCR-binding CIDRα1 domain of PfEMP1

嵌合型和鸡尾酒型衣壳病毒样颗粒疫苗用于诱导针对 PfEMP1 的 EPCR 结合 CIDRα1 结构域的抗体

Ilary Riedmiller, Cyrielle Fougeroux, Rasmus W Jensen, Ikhlaq H Kana, Adam F Sander, Thor G Theander, Thomas Lavstsen, Louise Turner

Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based Vaccine

衣壳病毒样颗粒疫苗可保护 K18-hACE2 小鼠免受 SARS-CoV-2 攻击

Sebenzile K Myeni, Anouk A Leijs, Peter J Bredenbeek, Shessy Torres Morales, Marissa E Linger, Cyrielle Fougeroux, Sophie van Zanen-Gerhardt, Serge A L Zander, Adam F Sander, Marjolein Kikkert

First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2

首次在人体中使用模块化衣壳病毒样疫苗平台:SARS-CoV-2 疫苗 ABNCoV2 的开放标签、非随机、1 期临床试验

Smit, Merel J; Sander, Adam F; Ariaans, Maud B P A; Fougeroux, Cyrielle; Heinzel, Constanze; Fendel, Rolf; Esen, Meral; Kremsner, Peter G; Ter Heine, Rob; Wertheim, Heiman F; Idorn, Manja; Paludan, Søren Riis; Underwood, Alexander P; Binderup, Alekxander; Ramirez, Santseharay; Bukh, Jens; Soegaard, Max; Erdogan, Sayit M; Gustavsson, Tobias; Clemmensen, Stine; Theander, Thor G; Salanti, Ali; Hamborg, Mette; de Jongh, Willem A; McCall, Matthew B B; Nielsen, Morten A; Mordmüller, Benjamin G

Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozyme

开发一种标签/捕手介导的衣壳病毒样颗粒疫苗,该疫苗呈递保守的淋病奈瑟菌 SliC 抗原,可阻断人类溶菌酶

Fabian G Martinez, Ryszard A Zielke, Cyrielle E Fougeroux, Lixin Li, Adam F Sander, Aleksandra E Sikora

Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature

基于衣壳病毒样颗粒平台的冷冻干燥可使疫苗在环境温度下稳定储存

Kara-Lee Aves, Christoph M Janitzek, Cyrielle E Fougeroux, Thor G Theander, Adam F Sander

An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice

S1纳米颗粒疫苗可保护K18-hACE2小鼠免受SARS-CoV-2病毒感染

van Oosten, Linda; Yan, Kexin; Rawle, Daniel J; Le, Thuy T; Altenburg, Jort J; Fougeroux, Cyrielle; Goksøyr, Louise; Adriaan de Jongh, Willem; Nielsen, Morten A; Sander, Adam F; Pijlman, Gorben P; Suhrbier, Andreas

SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition

在疫情早期,自然感染和疫苗接种诱导产生的SARS-CoV-2 RBD特异性抗体表现出交叉变异株结合和抑制作用

Walker, Melanie R; Podlekareva, Daria; Johnsen, Stine; Leerhøy, Bonna; Fougeroux, Cyrielle; Søgaard, Max; Salanti, Ali; Ditlev, Sisse Bolm; Barfod, Lea

Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021

2021 年 7 月坦桑尼亚东北部疟疾测量调查中招募的儿童和青少年中 SARS-CoV-2 抗体的血清流行率

Eric Lyimo, Cyrielle Fougeroux, Anangisye Malabeja, Joyce Mbwana, Paul M Hayuma, Edwin Liheluka, Louise Turner, Samwel Gesase, Thomas Lavstsen, John P A Lusingu, Daniel T R Minja, Christian W Wang